• In late June 2026, Glaukos Corporation announced it had fully enrolled 275 patients in a Phase 2 trial of GLK-321, a cream-based eyelid therapy using its iLution drug-delivery platform for Demodex blepharitis, while also being removed from two Russell 2000 defensive sub-indexes.
• The progress of GLK-321 underscores Glaukos’ push to extend its ophthalmic pipeline beyond glaucoma into underdiagnosed eyelid diseases with potentially more convenient, dropless treatment options.
• We’ll now examine how GLK-321’s clinical progress, alongside iDose TR momentum, may influence Glaukos’ existing investment narrative and risk profile.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

Glaukos Investment Narrative Recap

To own Glaukos, you need to believe in its shift toward interventional, dropless eye care anchored by iDose TR, while accepting ongoing losses and reimbursement uncertainty. The GLK-321 Phase 2 enrollment milestone supports that long-term pipeline story, but is unlikely to move the near term iDose TR reimbursement and adoption catalyst or the key risk around pricing and utilization. Removal from two Russell defensive sub-indexes may affect trading, not the underlying business.

Among recent announcements, the FDA’s January 2026 approval of repeat administration labeling for iDose TR looks most relevant. That decision reinforces iDose TR as Glaukos’ central growth driver and frames GLK-321 and the iLution platform as potential extensions of a broader, dropless treatment ecosystem. Together, they highlight how much of the current thesis still turns on execution in glaucoma while new assets like GLK-321 remain clinically and commercially unproven.

Yet behind the strong product story, investors should also be aware of the growing reimbursement and pricing pressures that could...

Glaukos’ narrative projects $1.1 billion revenue and $113.0 million earnings by 2029.

Uncover how Glaukos' forecasts yield a $157.50 fair value, a 3% upside to its current price.

Exploring Other Perspectives

While consensus leans on iDose TR strength, the most cautious analysts highlight reimbursement pressure and saw only about US$890.7 million revenue and US$60.7 million earnings by 2029, reminding you that opinions can diverge sharply and that new data like GLK-321’s progress and index removal may shift these views over time.

Explore 4 other fair value estimates on Glaukos - why the stock might be worth 11% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Glaukos research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Glaukos research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Glaukos' overall financial health at a glance.

Contemplating Other Strategies?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• Find 44 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.